← Human Trials & Peer-Reviewed Studies
Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes
Plain-language guide to PMID 20399326 (2010): double-blind randomized controlled trial study of Exenatide in 194 patients.
Key Facts
- PMID
- 20399326
- Journal
- The American journal of medicine
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- Apovian CM et al. (7 authors)
- DOI
- 10.1016/j.amjmed.2009.11.019
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exenatide, published as a randomized controlled trial.
To determine the effect of a lifestyle modification program plus exenatide versus lifestyle modification program plus placebo on weight loss in overweight or obese participants with type 2 diabetes treated with metformin and/or sulfonylurea.
Who Took Part
The abstract describes 194 patients taking part.
The age groups tagged for this paper are teenagers, adults, middle-aged adults and older adults, both men and women.
In this 24-week, multicenter, randomized, double-blind, placebo-controlled study, 194 patients participated in a lifestyle modification program, consisting of goals of 600 kcal/day deficit and physical activity of at least 2.5 hours/week.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.
The patients were allocated by chance, so the Exenatide group and the comparison group should start out alike.
Neither the patients nor the staff measuring them knew who was on Exenatide, so expectations could not easily colour the readings.
Some patients received a placebo instead of Exenatide, giving a reference point.
Running at several centres spread the Exenatide study over different clinics and patient groups.
What Was Measured
PubMed files the paper under topics including Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Exenatide, Glucagon-Like Peptide 1, Hypoglycemic Agents and Life Style.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exenatide in 194 patients.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2010 (The American journal of medicine), a journal based in United States.
More context: the Exenatide compound page, all human trials.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.